Market Cap (In GBp)
8.4 Million
Revenue (In GBp)
-
Net Income (In GBp)
-8.4 Million
Avg. Volume
285.23 Thousand
- Currency
- GBp
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 3.0-10.0
- PE
- -
- EPS
- -
- Beta Value
- -2.226126
- ISIN
- GB00B0381Z20
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Richard Marsden
- Employee Count
- -
- Website
- https://www.synairgen.com
- Ipo Date
- 2004-10-26
- Details
- Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
More Stocks
-
BTTC
-
NKLANikola Corporation
NKLA
-
ROSTRoss Stores, Inc.
ROST
-
PZZA
-
MARZFMarston's PLC
MARZF
-
000680
-
BESTEASTBest Eastern Hotels Limited
BESTEAST
-
SWKS